ArtiQ and Boehringer Ingelheim join forces to help bring expertise on all care levels

Pulmonary fibrosis (IPF) belongs to a group of so-called interstitial lung diseases (ILD) and is a condition leading to a build-up of scar tissue in the lungs. Over time, the lungs lose their ability to take in and transfer oxygen into the bloodstream.

IPF is a progressive and life-threatening lung disease that can cause permanent damage to the lungs right from the start. Early diagnosis and treatment of IPF are critical because acting quickly can make a difference. However, research shows that the time from first symptoms to diagnosis is often still very long due to the rareness of the disease and the concentrated expertise in the expert centers. Many patients experience an initial misdiagnosis or a delayed referral to a CT scan or an ILD specialist center.

Recently the ArtiQ team joined forces with Boehringer Ingelheim, a global leader in providing pharmaceutical solutions for patients with IPF among other lung diseases. They share our belief that international partnerships can support improved standards of care for people suffering from life-changing conditions such as lung diseases. Therefore, it is no surprise that we met during the Start-up Meets Pharma program of EIT Health.

This partnership will bring the ArtiQ technology to a focused group of hospitals across multiple countries to help improve the diagnostic process for medical professionals and patients alike.